Tg Therapeutics, Inc. (TGTX) Stock Price & Analysis

Tg Therapeutics, Inc. (TGTX) rose 0.00% to USD 56.04 as of July 25, 2026 at 04:23 UTC, according to Nexqual real-time market data.

TGTX last closed at USD 56.04; the session ranged USD 53.86–56.45 on volume of 1,384,857 shares. Market capitalization is —, with a 52-week range of USD 25.28–59.3 (NCM). Source: Nexqual, July 25, 2026 at 04:23 UTC.

Key Statistics (as of July 25, 2026 at 04:23 UTC)

Technical Analysis (TGTX)

Nexqual's technical model rates TGTX "STRONG BUY" based on 5 bullish and 0 bearish signals across 125 daily candles, as of July 25, 2026 at 04:23 UTC.

From Tg Therapeutics, Inc.'s Latest SEC 10-K Filing (filed 2026-02-27)

Key Strengths & Strategy (as disclosed to the SEC)

• To this end, we seek to protect our proprietary technology and processes, in part, by entering into confidentiality agreements with our collaborators, scientific advisors, employees and consultants, and invention assignment agreements with our employees and consultants.
• Before marketing in the U.S., any drug that we develop must undergo rigorous pre-clinical testing and clinical trials and an extensive regulatory review and approval process implemented by the FDA under the Federal Food, Drug, and Cosmetic Act (FDCA) and, in the case of biologics, the Public Health Service Act.
• Our policy is to actively seek to obtain, where appropriate, the broadest intellectual property protection possible for our product candidates, proprietary information and proprietary technology through a combination of contractual arrangements and patents, both in the U.S. and elsewhere in the world.   We also depend upon the skills, knowledge and experience of our scientific and technical personnel, as well as that of our advisors, consultants and other contractors.
• This knowledge, trade secrets, proprietary information and experience we call "know-how." To help protect our proprietary know-how, which is not patentable, and for inventions for which patents may be difficult to enforce, we rely on trade secret protection and confidentiality agreements to protect our interests.

Partnerships

• Commercialization of BRIUMVI   In August 2023, we entered into a Commercialization Agreement with Neuraxpharm, a leading European specialty pharmaceutical company focused on the treatment of CNS disorders, for the ex-U.S. commercialization of BRIUMVI.
• During this 12-year period, which extends until December 2034, a biosimilar product that references our BRIUMVI product cannot be approved.  ​ Azer-Cel (allogeneic CD19 CAR T)   Pursuant to our license agreement with Precision, we have an exclusive license to develop and commercialize Precision's azer-cel for the treatment of autoimmune and other non-oncology diseases and conditions as well as a non-exclusive license to manufacture azer-cel.

Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.

Peers & Related Stocks

Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: July 25, 2026 at 04:23 UTC. This page is informational and not investment advice.